EMA Authorised: Kadcyla (trastuzumab emtansine) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorised Kadcyla (trastuzumab emtansine) by Roche Registration GmbH for breast cancer, with decision date 19 February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Roche Registration GmbH. Decision date: 19/02/2026